Successful Treatment with High-dose Steroids for Acute Exacerbation of Idiopathic Pulmonary Fibrosis Triggered by COVID-19

Intern Med. 2022 Jan 15;61(2):233-236. doi: 10.2169/internalmedicine.8163-21. Epub 2021 Nov 6.

Abstract

We herein report a case of acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) triggered by COVID-19. An 87-year-old woman tested positive for COVID-19 on a polymerase chain reaction test, and computed tomography revealed ground-glass opacity (GGO) superimposed on a background pattern consistent with usual interstitial pneumonia. Considering these data, we diagnosed her with AE-IPF. She experienced worsening of dyspnea and expansion of the GGO. Therefore, we introduced high-dose steroids (methylprednisolone 250 mg/day for 3 days). After the treatment, the pulmonary infiltrates improved. She was discharged from our hospital without severe disability. High-dose steroids can be a viable treatment option for AE-IPF triggered by COVID-19.

Keywords: COVID-19; acute exacerbation; case report; high-dose steroid; idiopathic pulmonary fibrosis.

Publication types

  • Case Reports

MeSH terms

  • Aged, 80 and over
  • COVID-19*
  • Disease Progression
  • Female
  • Humans
  • Idiopathic Pulmonary Fibrosis* / drug therapy
  • SARS-CoV-2
  • Steroids

Substances

  • Steroids